Table 1 Baseline clinical characteristics of participants
Items | Participants |
|---|---|
No. of patients (male/female) | 10 (5/5) |
Age (years) | 64.1 ± 10.6 |
Duration of RA (years) | 8.4 ± 11.0 |
Cr (mg/dL) | 0.66 ± 0.12 |
BUN (mg/dL) | 15.6 ± 4.9 |
AST (IU/L) | 20.5 ± 3.3 |
ALT (IU/L) | 23.3 ± 11.6 |
MCV (fL) | 97.8 ± 2.5 |
CRP (mg/dL) | 0.2 ± 0.2 |
SDAI | 5.4 ± 4.0 |
DAS28-CRP | 2.1 ± 0.8 |
MMP-3 (ng/mL) | 130.2 ± 88.6 |
MTX (mg/week) | 7.0 ± 3.0 |
MTX dosage at first dose each week | |
4 mg (No. of patients) | 5 |
2 mg (No. of patients) | 5 |
SASP (mg/day) | 1000 ± 0 |
PSL (mg/day) | 2.7 ± 2.7 |
No. of drugs being taken | 6.0 ± 2.1 |